A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease

Journal of Ayurveda and Integrative Medicine

Volumn 1, Issue 3, 2010, Pages 203-210

  Shetty, Sapna N ^a   Mengi, Sushma ^a   Vaidya, Rama ^a   Vaidya, Ashok D B ^a  

^a Genetic Research Centre India   (India)

Author keywords

Hepatoprotective; high fat diet; insulin resistance; metabolic syndrome; non alcoholic fatty liver; Picrorhiza kurroa reverse pharmacology

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; LIPID; PICRORHIZA KURROA EXTRACT; PICROSIDE I; SILYMARIN; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASH; BODY WEIGHT; BUTTER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANALYSIS; DRUG ISOLATION; HISTOPATHOLOGY; LIPID DIET; LIPID LIVER LEVEL; LIVER INJURY; LIVER PROTECTION; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79952903496     PISSN: 09759476     EISSN: 09762809     Source Type: Journal    
DOI: 10.4103/0975-9476.72622     Document Type: Article

References (54)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8. (Pubitemid 10057164)
2. Rodrigues-Hernandez H, Gonzalez JL, Marquez-Ramirez MD, Flores-Hernandez M, Rodrizues-Morian M, Guerrero-Romero F. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. Eur J Gastroenterol Hepatol 2008;20:399-403. (Pubitemid 351533876)
3. Verrijken A, Francque S, Van Gaal L. The metabolic syndrome and the liver. Acta Gastroenterol Belg 2008;71:48-59. (Pubitemid 351613489)
4. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of Type 2 diabetes: Indian Scenario. Indian J Med Res 2007;125:217-30. (Pubitemid 46805444)
5. Stefan N, Kantartzis K, Hring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-60.
6. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association, National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8. (Pubitemid 38133916)
7. Stern M, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of Type 2 diabetes or cardiovascular disease? Diabetes Care 2004;27:2676-81. (Pubitemid 39441469)
8. Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, et al. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 2009; 9:271.
9. Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS, Thomas GN, et al. Factor analysis of the metabolic syndrome: Obesity vs insulin resistance as the central abnormality. Int J Obes 2001;25:1782.
10. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008;70:193-219.
11. Paul A, Keith DL. Treatment of nonalcoholic fatty liver: Present and emerging therapies. Semin Liver Dis 2001;21:81-8.
12. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 1970;282:829-34.
13. Vaidya AB, Sirsat MS, Doshi JC, Antarkar DS. Selected medicinal plants and formulations as hepato-biliary drugs: An Over-view. Clin Pharmacol Ther 1996;14:7-11.
14. Dwivedi Y, Rastogi R, Ramesh C, Sharma SK, Kapoor NK, Garg NK, et al. Hepatoprotective activity of Picroliv against carbon tetrachloride induced liver damage in rats. Indian J Med Res 1990;92b:195-200.
15. Visen PK, Shukla B, Patnaik GK, Dhawan BN. Prevention of galactosamine-induced hepatic damage by Picroliv: Study on bile flow and isolated hepatocytes. Planta Med 1993;59:37-41. (Pubitemid 23055644)
16. Dwivedi Y, Rastogi R, Garg NK, Dhawan BN. Prevention of paracetamol-induced hepatic damage in rats by Picroliv, the standardized active fraction from Picrorhiza kurroa. Phytother Res 1991;5:115-9.
17. Dwivedi Y, Rastogi R, Sharma SK, Garg NK, Dhawan BB. Picroliv affords protection against thioacetamide-induced hepatic damage in rats. Plant Med 1991;57:25-8.
18. Pandey VN, Chaturvedi GN. Effect of indigenous drug kutaki on bile after producing biliary fistula in dogs. Indian J Med Res1970;5:1-24.
19. Vaidya AB, Antarkar DS, Doshi JC, Bhat AD, Ramesh V, Vora PV, et al. Picrorhiza kurroa (Kutaki) Royle ex Benth as a hepatoprotective agent-experimental and clinical studies. J Postgrad Med 1996;42:105-8. (Pubitemid 126729346)
20. Antarkar DS, Tathed PS, Vaidya AB. A pilot phase II trial with Arogyawardhini and Punarnavadi kwath in viral hepatitis. Panminerva Med 1978;20:157-63.
21. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: From bench to bed side. Anticancer Res 2006;26:4457-98. (Pubitemid 46031522)
22. Giese LA. Milk thistle and the treatment of hepatitis. Gastroenterol Nurs 2001;24:95-7.
23. Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, et al. Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCl(4)-induced hepatic fibrosis. World J Gastroenterol 2005;11:1141-8.
24. Zieliska-Przyjemska M, Wiktorowicz K. An in vitro study of the protective effect of the flavonoid silydianin against reactive oxygen species. Phytother Res 2006;20:115-9. (Pubitemid 43266835)
25. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996;23:749-54. (Pubitemid 26111988)
26. Folch J, Lees M, Soane GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
27. Rastogi RP, Dhawan BN. Research on medicinal plants at the Central Drug Research Institute, Lucknow (India). Indian J Med Res 1982;76:27-45. (Pubitemid 13102724)
28. Cankurtaran M, Tayfur O, Yavuz BB, Gevik S, Akhan O, Arslan S. Insulin resistance and metabolic syndrome in patients with NAFLD but without diabetes: effect of a 6 month regime intervention. Acta Gastroenterol Belg 2007;70:253-9. (Pubitemid 350086040)
29. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in Nonalcoholic fatty liver disease. Curr Pharm Des 2010;16:1941-51.
30. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 2009;26:893-907.
31. Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 2009;40:571-5.
32. Vanni E, Bugianesi E, Kotronen A, Minicis S, Yki-Jrvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42:320-30.
33. Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: A preliminary ultrasonographic survey. Trop Gastroenterol 2004;25:76-9.
34. Madan K, Batra Y, Acharya SK. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol 2006;12:3400-5. (Pubitemid 43933786)
35. Patel AA, Torres DM, Harrison SA. Effect of weight loss on non-alcoholic fatty liver disease. J Clin Gastroenterol 2009;43:970-4.
36. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes Rev 2010;11:430-45.
37. Haukeland JW, Konopski Z, Eggesb HB, von Volkmann HL, Raschpichler G, Bjro K, et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol 2009;44:853-60.
38. Uzun MA, Koksal N, Aktas S, Gunerhan Y, Kadiogly H, Dursun N, et al. The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease. Hepatol Res 2009;39:814-21.
39. Angulo P. Treatment of non-alcoholic fatty liver disease. Ann Hepatol 2002;1:12-9.
40. Wang Z, Yao T, Pini M, Zhou Z, Fantuzzi G, Song Z. Betaine improved adipose tissue function in mice fed high-fat diet: A mechanism for hepatoprotective effect of betaine in non-alcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2010;298:G634-42.
41. Panchabhai TS, Ambarkhane SV, Joshi AS, Samant BD, Rege NN. Protective effect of Tinospora cordifolia, Phyllanthus emblica and their combination against antitubercular drugs induced hepatic damage: An experimental study. Phytother Res 2008;22:646-50. (Pubitemid 351716553)
42. Pilankar PD. A study of hepatoprotective effects of some indigenous plants in experimental animals. Ph.D. Thesis. University of Mumbai. 1981.
43. Singh B, Rastogi RP. Chemical examination of Picrorhiza kurroa Part VI: Re-investigation of Kutkin. Indian J Chem 1972;10:29-31.
44. Sharma PV. Classical uses of medicinal plants. Chaukhambha Visvabharati. Varanasi, India. 1996;69.
45. Koolman AH, Bloks VW, Oosterveer MH, Jonas I, Kuipers F, Sauer PJ, et al. Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition. Int J Obes (Lond) 2010;34:374-84.
46. Brunt EM. Nonalcoholic steatohepatitis: Definition and Pathology. Semin Liver Disease 2001;21:3-16. (Pubitemid 32240482)
47. Pan M, Song YL, Xu JM, Gan HZ. Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. J Pineal Res 2006;41:79.
48. Pandey BL, Das PK. Immunopharmacological studies on Picrorhiza kurroa Royle-Ex-Benth. Part V: Anti-inflammatory action: Relation with cell types involved in inflammation. Indian J Physiol Pharmacol 1988;32:289-92. (Pubitemid 18268800)
49. Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol 2006;98:1231-3. (Pubitemid 44584113)
50. Dunbar RL, Rader DJ. Current drug options for raising HDL cholesterol. Curr Treat Options Cardiovasc Med 2005;7:15-23. (Pubitemid 40894651)
51. Liu R, Pan X, Whitington PF. Increased hepatic expression is a major determinant of serum alanine aminotransferase elevation in mice with nonalcoholic steatohepatitis. Liver Int 2009;29:337-43.
52. Budd RC. Death receptors couple to both cell proliferation and apoptosis. J Clin Invest 2002;109:437-42. (Pubitemid 34171772)
53. Menon NK, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol 2001;96:1631.
54. Sorrentino P, Tarantino G, Perrella A, Micheli P, Perella O, Conca P. A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. Dig Dis Sci 2005;50:1130-5. (Pubitemid 40864022)